2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1535

Use of Rituximab Compared to Anti-Tnf Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: A Report from the rhumadata® Clinical Database and registry
Abstract Number: 675

Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience
Abstract Number: 110

Use of Smartphones in Collecting Patient Reported Outcomes: Can Passively-Collected Behavior Determine Rheumatic Disease Activity? Early Results from a Nation-Wide Pilot Study
Abstract Number: 2332

Use of Wrist Hand Orthoses during Hand Function Skills and Functional Tasks By Adults with and without Rheumatoid Arthritis
Abstract Number: 2992

Usefulness of Diagnostic Biomarker for Neuropsychiatric Systemic Lupus Erythematosus By Anti-Microtubule Associated Protein 2 Antibody in Cerebrospinal Fluid
Abstract Number: 2882

Using Decision-Based Learning to Highlight Rheumatic Disease for Third-Year Medical Students
Abstract Number: 2595

Using Iphone Compass Application for the Assessment of Cervical Rotation in Patients with Ankylosing Spondylitis
Abstract Number: 384

Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient Activity Score (PAS) and Routine Assessment of Patient Index Data (RAPID)
Abstract Number: 416

Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient-Derived Versions of Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and Disease Activity Score 28 (DAS28)
Abstract Number: 2007

Using Photovoice Techniques to Empower Lupus Patients and Create Public Awareness: A Program Evaluation
Abstract Number: 286

Using the 2011 ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis (JIA) to Evaluate a Single Centre Treatment Pathway: A Feasibility Study
Abstract Number: 376

Using the Multi-Biomarker Disease Activity Score As a Complementary Inclusion Criterion for Clinical Trials in Rheumatoid Arthritis May Enhance Recruitment
Abstract Number: 1168

Usng an Advanced Clinician Practitioner in Arthritis Care Trained Physiotherapist and a Standardized Electronic Medical Record Triage Assessment Tool to Detect Inflammatory Arthritis and Initiate Dmards Earlier in a Community Rheumatology Office Setting
Abstract Number: 704

Utility and Associated Risk of Pulmonary Embolism CT Scans in the Michigan Lupus Cohort
Abstract Number: 2479

Utility of Adjustment of Administration Interval in Tocilizumab in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].